Document is current
Any future updates will be listed below
-
Authors
Huttner, Hagen B.
Scherg, Felix
Kopke, Katarina
Schultze, Michael
Kossack, Nils
Gerner, Stefan T.
Kuramatsu, Joji B.
Schwab, Stefan
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 1 November 2024
Accepted: 2 January 2025
First Online: 31 March 2025
Declarations
:
: The observational, retrospective study used anonymised data, which was recorded for reimbursement purposes and is compliant with German data protection regulations. Accordingly, approval of an institutional review board or ethics committee was not required.
: Not applicable.
: HH has received honoraria for lectures, consulting and funding from AstraZeneca and Portola Pharmaceuticals. SS has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pfizer, and Bayer Pharma. FS and KK are employees of AstraZeneca which funded this study. MS is an employee of ZEG Berlin, which received funding from AstraZeneca to conduct this study. NK is an employee of WIG2, which received funding from AstraZeneca to conduct this study. SG has received honoraria for lectures from Boehringer Ingelheim, BMS-Pfizer, Novartis, as well as Bayer Pharma, and received funding from AstraZeneca to conduct this study. JK has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, and BMS-Pfizer, and has received honoraria for consulting from AstraZeneca.
